Meeting
2015 ASCO Annual Meeting
Analysis of the prognostic value of the tumor immunologic profile in resectable NSCLC.
Authors
Marta Usó
Fundación para la Investigación del Hospital General Universitario de Valencia, Valencia, Spain
Marta Usó , Eloisa Jantus-Lewintre , Rafael Sirera , Silvia Calabuig-Fariñas , Ana Blasco , Ricardo Guijarro , Enrique Pastor , Carlos Camps
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Immunobiology
Citation
J Clin Oncol 33, 2015 (suppl; abstr 11052)
DOI
10.1200/jco.2015.33.15_suppl.11052
Abstract #
11052
Poster Bd #
265
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).
First Author: Tian Zhang
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A transcriptomic approach to explore the immune landscape of patient with pancreatic ductal adenocarcinoma with prognostic impact.
First Author: Jose Antonio Lopez Guerrero
Poster
2021 ASCO Annual Meeting
Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.
First Author: Katherine L. Pogue-Geile
Poster
2017 ASCO Annual Meeting
Interplay between immune infiltration and tumor progression and survival in non-small cell lung cancer: An analysis of institutional and public data.
First Author: Ali Jalali